Video
Improvements in bone-metastasis-related pain and QoL demonstrated in mCRPC with Lutetium-177 PSMA-617
Author(s):
Video Player is loading.
In this video, Brian D. Gonzalez, PhD, discusses the background, findings, and takeaways of the study, “Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gonzalez is an associate member and quality of life researcher at Moffitt Cancer Center in Tampa, Florida.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Related Content
